(Q40299053)

19 September 2017

1 reference

title

The pathogenesis and treatment of pulmonary infections in patients with cystic fibrosis (English)

1 reference

19 September 2017

0 references

Marks MI

1

1 reference

19 September 2017

language of work or name

English

0 references

publication date

1 February 1981

1 reference

The Journal of Pediatrics

19 September 2017

published in

1 reference

19 September 2017

volume

98

1 reference

19 September 2017

issue

2

1 reference

19 September 2017

page(s)

173-179

1 reference

Research in cystic fibrosis (first of three parts)

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980631-2

Research in cystic fibrosis (second of three parts)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980631-2

Research in cystic fibrosis (third of three parts).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980631-2

Antibodies to proteases and exotoxin A of Pseudomonas aeruginosa in patients with cystic fibrosis: Demonstration by radioimmunoassay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980631-2

Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980631-2

Influence of Mucoidy on Antibody Coating of Pseudomonas aeruginosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980631-2

Inhibitory effect of cystic fibrosis serum on pseudomonas phagocytosis by rabbit and human alveolar macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980631-2

Development of cellular and humoral immunity in the respiratory tract of rabbits to Pseudomonas lipopolysaccharide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980631-2

Immune Complexes in Cystic Fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980631-2

Lymphocyte responsiveness to Pseudomonas aeruginosa in cystic fibrosis: Relationship to status of pulmonary disease in sibling pairs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980631-2

Staphylococcus aureus: some host-parasite interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980631-2

Bronchial infection in cystic fibrosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980631-2

The key role of peptidoglycan in the opsonization of Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980631-2

A placebo-controlled trial of cephalexin therapy in the ambulatory management of patients with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980631-2

Is anti-Pseudomonas therapy warranted in acute respiratory exacerbations in children with cystic fibrosis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980631-2

Pharmacokinetics of Methicillin in Patients with Cystic Fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980631-2

Bacterial colonization and clinical superinfection of the respiratory tract complicating antibiotic treatment of pneumonia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980631-2

Effect of Calcium and Magnesium Ions on the Susceptibility of Pseudomonas Species to Tetracycline, Gentamicin Polymyxin B, and Carbenicillin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980631-2

Mucoid Pseudomonas aeruginosa and cystic fibrosis: resistance of the mucoid form to carbenicillin, flucloxacillin and tobramycin and the isolation of mucoid variants in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980631-2

Multiple Isolates of Pseudomonas aeruginosa with Differing Antimicrobial Susceptibility Patterns from Patients with Cystic Fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980631-2

Carbenicillin and gentamicin: pharmacologic studies in patients with cystic fibrosis and pseudomonas pulmonary infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980631-2

Carbenicillin: A Clinical and Laboratory Evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980631-2

Summary of a Workshop on Infections in Patients with Cystic Fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980631-2

Azlocillin in respiratory tract infections with Pseudomonas aeruginosa in children with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980631-2

Incidence and Characteristics of Antibiotic-Tolerant Strains of Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980631-2

Pseudomonas colonization in cystic fibrosis. A study of 160 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980631-2

Activity of newer aminoglycosides and carbenicillin, alone and in combination, against gentamicin-resistant Pseudomonas aeruginosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980631-2

Controlled Comparison of Amikacin and Gentamicin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980631-2

Nephrotoxicity with gentamicin or tobramycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980631-2

HR 756, a Highly Active Cephalosporin: Comparison with Cefazolin and Carbenicillin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980631-2

LY-127935: a novel beta-lactam antibiotic with unusual antibacterial activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980631-2

In vitro antibacterial activity of cefoperazone (T-1551), a new semisynthetic cephalosporin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980631-2

Comparative Evaluation of Piperacillin in Vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980631-2

Comparative Study of Anti-Pseudomonas Activity of Azlocillin, Mezlocillin, and Ticarcillin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980631-2

Treatment of pulmonary infections in patients with cystic fibrosis: A comparative study of ticarcillin and gentamicin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980631-2

Microscopic characterization of rabbit lung damage produced by Pseudomonas aeruginosa proteases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980631-2

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0022-3476(81)80631-2

1 reference

19 September 2017

1 reference